Tessera un­veils promis­ing in vi­vo gene edit­ing treat­ment for sick­le cell in an in­creas­ing­ly com­pet­i­tive field: #AS­GCT24

Tessera Ther­a­peu­tics, a well-fund­ed start­up based out­side of Boston, an­nounced Fri­day that it de­vel­oped a lipid nanopar­ti­cle that shut­tles a gene edit­ing ther­a­py di­rect­ly to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.